Jun 27,2024

ABBOTT HOSTS CONFERENCE CALL FOR SECOND-QUARTER EARNINGS

Abbott will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

View Analyst & Ambassador Comments
Go to original news
Jun 06,2024

Medtronic chairman and CEO Geoff Martha to speak at Goldman Sachs global healthcare conference

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 45th annual Goldman Sachs global healthcare conference on Tuesday, June 11, 2024. Geoff Martha, Medtronic chairman and chief executive officer, will answer questions on the company beginning at 10:40 a.m. EDT (9:40 a.m. CDT).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 03,2024

Abbott receives FDA OK for over-the-counter glucose monitor

Abbott has received FDA approval for its over-the-counter glucose monitor, Lingo, which first launched in the U.K. last year. The device is designed for non-diabetics to track glucose spikes. With this clearance, Abbott joins the market alongside Dexcom, which received similar FDA approval for its CGM, Stelo, in March. Abbott has yet to announce the rollout details for Lingo in the U.S.  Abbott plans to market Lingo under a direct-to-consumer, cash-pay model that doesn’t need a prescription.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
May 06,2024

Xeris enters into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

Xeris Biopharma Holdings, Inc. has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. to develop and commercialize a new liquid stable glucagon formulation using Xeris’ XeriSol™ technology. This glucagon will be used in Beta Bionics’ bi-hormonal pump systems, designed to improve glucose control for people with diabetes by providing both insulin and glucagon. Xeris will be the exclusive glucagon provider, and the agreement includes potential development payments to Xeris and low double-digit royalties on future sales.

COLLABORATION PARTNERSHIP

#r&d

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 04,2024 TOP STORY

OptiMed adds Vida Health as a Preferred Partner, Introducing Innovative Anti-Obesity Medication Management Program

OptiMed Health Partners has named Vida Health as a preferred partner to enhance their cardiometabolic care services, particularly in clinical obesity management. This collaboration will enable OptiMed to integrate Vida Health's comprehensive virtual care, including anti-obesity medication management, diabetes support, and behavior change coaching, for their members. Vida Health will serve as a center of excellence for anti-obesity medications, ensuring that only prescriptions from their qualified professionals are covered under OptiMed's benefits plan.

COLLABORATION PARTNERSHIP

#insurance

#coaching

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jun 05,2024

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

GlucoTrack, Inc. announced successful results from a 90-day preclinical study of its Continuous Blood Glucose Monitor (CBGM), demonstrating sustained accuracy with a Mean Absolute Relative Difference (MARD) of 4.7%, indicating high precision. The CBGM offers a simplified, discreet, and less intrusive method for continuous glucose monitoring, directly measuring blood glucose in real-time, unlike subcutaneous sensors. The study, which included more subjects and a longer duration than previous studies, validated the device's performance without significant adverse effects. GlucoTrack plans to start human clinical trials later this year, aiming to enhance the quality of life for people with diabetes by providing a convenient monitoring solution.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 05,2024

Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

DarioHealth Corp. has announced a strategic reorganization to enhance its commercial expansion, highlighted by the appointment of Steven Nelson as the inaugural Chief Commercial Officer (CCO). The reorganization aims to accelerate DarioHealth’s market impact and commercialization efforts, especially following their expanded product offering through the Twill acquisition. Nelson, with over two decades of experience in scaling healthcare companies, will oversee global commercial activities, including growth strategy, sales, marketing, and partnerships. This reorganization involves eliminating the President role and creating dedicated C-level positions to streamline leadership and drive profitability.

View Analyst & Ambassador Comments
Go to original news
Jun 04,2024

Dexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 Diabetes

Dexcom announced a significant advancement in access to its products for those treating Type 2 diabetes (T2D) with basal insulin injections. The company has secured access to its Dexcom ONE sensor for around 100,000 T2D users in France. The reimbursement guidance offers people aged over two years who are on non-intensified insulin therapy (less than 3 injections a day) and whose glycaemic control is insufficient (HbA1c ≥ 8%) access to Dexcom’s technology. The French government is the first in Europe to offer full national reimbursement for Dexcom CGM technology to those treating T2D with basal injections, following other countries around the world such as the USA and New Zealand.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 05,2024

Dexcom G7 Now Connects Directly to Apple Watch in the U.S.

DexCom announced that the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects directly to Apple Watch in the United States. Dexcom G7 is the first and only CGM available with Direct to Apple Watch, offering users the freedom and convenience of real-time glucose readings on their wrist even when their iPhone isn’t with them. In addition to the benefits of using Direct to Apple Watch with Dexcom G7, people with diabetes can track other key health metrics that can impact glucose levels using Apple’s Activity, Cycle Tracking, Sleep, and other health features on Apple Watch, iPhone and iPad. All of this data is stored securely in the Health app, where it can be viewed alongside Dexcom G7 data users choose to store in the Health app so all of their diabetes health information is accessible in one place.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 29,2024

Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM

Tandem Diabetes Care and Dexcom have announced that the Tandem Mobi insulin pump, which features Control-IQ technology, is now fully compatible with both the Dexcom G6 and G7 Continuous Glucose Monitoring (CGM) systems. Launched in the US earlier this year, the Tandem Mobi is the world's smallest automated insulin delivery (AID) system. This integration makes Tandem the only company offering two insulin pump options that work with both Dexcom G6 and G7, enhancing user choice in diabetes management. Current Tandem Mobi users in the US will receive a software update for this feature, available free of charge, while new customers will receive pumps with the updated software.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES